

Enhanced Drug List Updates

October 2018

TRADE NAME (generic name) or generic name	Brand/Generic Product	Description of Change
ALINIA (nitazoxanide for susp 100 mg/5ml)	Brand	Addition, Preferred Status
ALINIA (nitazoxanide tab 500 mg)	Brand	Addition, Preferred Status
ARNUITY ELLIPTA (fluticasone furoate aerosol powder breath activ 50 mcg/act)	Brand	Addition, Preferred Status
BIKTARVY (bictegravir-emtricitabine-tenofovir af tab 50-200-25 mg)	Brand	Addition, Preferred Status
CHLOROQUINE PHOSPHATE (chloroquine phosphate tab 250 mg)	Brand	Addition, Preferred Status
CIMDUO (lamivudine-tenofovir disoproxil fumarate tab 300-300 mg)	Brand	Addition, Preferred Status
CREON (pancrelipase (lip-prot-amyl) dr cap 12000-38000-60000 unit)	Brand	Addition, Preferred Status
CREON (pancrelipase (lip-prot-amyl) dr cap 24000-76000-120000 unit)	Brand	Addition, Preferred Status
CREON (pancrelipase (lip-prot-amyl) dr cap 3000-9500-15000 unit)	Brand	Addition, Preferred Status
CREON (pancrelipase (lip-prot-amyl) dr cap 36000-114000-180000 unit)	Brand	Addition, Preferred Status
CREON (pancrelipase (lip-prot-amyl) dr cap 6000-19000-30000 unit)	Brand	Addition, Preferred Status
ERLEADA (apalutamide tab 60 mg)	Brand	Addition, Preferred Status
HUMIRA (adalimumab prefilled syringe kit 10 mg/0.1ml)	Brand	Addition, Preferred Status
HUMIRA (adalimumab prefilled syringe kit 20 mg/0.2ml)	Brand	Addition, Preferred Status
HUMIRA (adalimumab prefilled syringe kit 40 mg/0.4ml)	Brand	Addition, Preferred Status
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK (adalimumab prefilled syringe kit 80 mg/0.8ml & 40 mg/0.4ml)	Brand	Addition, Preferred Status
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK (adalimumab prefilled syringe kit 80 mg/0.8ml)	Brand	Addition, Preferred Status
HUMIRA PEN (adalimumab pen-injector kit 40 mg/0.4ml)	Brand	Addition, Preferred Status
IDELVION (coagulation factor ix (recomb) (rix-fp) for inj 3500 unit)	Brand	Addition, Preferred Status
MEFLOQUINE HCL (mefloquine hcl tab 250 mg)	Brand	Addition, Preferred Status
NORVIR (ritonavir powder packet 100 mg)	Brand	Addition, Preferred Status
SYMFI (efavirenz-lamivudine-tenofovir df tab 600-300-300 mg)	Brand	Addition, Preferred Status
SYMFI LO (efavirenz-lamivudine-tenofovir df tab 400-300-300 mg)	Brand	Addition, Preferred Status
TASIGNA (nilotinib hcl cap 50 mg (base equivalent))	Brand	Addition, Preferred Status
TOUJEO MAX SOLOSTAR (insulin glargine soln pen-injector 300 unit/ml)	Brand	Addition, Preferred Status
ZENPEP (pancrelipase (lip-prot-amyl) dr cap 10000-32000-42000 unit)	Brand	Addition, Preferred Status
ZENPEP (pancrelipase (lip-prot-amyl) dr cap 15000-47000-63000 unit)	Brand	Addition, Preferred Status
ZENPEP (pancrelipase (lip-prot-amyl) dr cap 3000-10000-14000 unit)	Brand	Addition, Preferred Status

Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC.